Studies show that a once-weekly semalutide injection can help people lose up to 12% of their weight in about a year and a half.
Semaglutide, to be sold under the brand name Wegovy by the manufacturer Novo Nordisk, affects a hormone known as semaglutide. glucagon-like peptide-1 and increases insulin production But it also seems to suppress appetite.
FDA Says New Obesity Treatment Needed
“About 70% of American adults are obese or overweight. Being obese or overweight is a serious health problem associated with some major causes of death, such as heart disease, stroke. and diabetes and has been linked to an increased risk of some cancers. The agency said in a statement.
“Reducing 5% to 10% of body weight from diet and exercise is associated with a reduced risk of cardiovascular disease in obese or overweight adult patients.”
Non-diabetics who took the drug lost an average of 12.4% of their initial body weight over 16 months, compared to those taking the placebo. The diabetics who tested the drug lost 6.2% more weight compared to those who received the placebo injection.
Some medications are specifically approved in the United States for weight loss. They include orlistat, sold under the brand name Xenical, which reduces the amount of fat the body absorbs; Qsymia, a drug that combines appetite-suppressing phentermine with the drug topiramate; Contrave, which combines addiction to naltrexone with the antidepressant bupropion; and liraglutide or Saxenda, which is a diabetes medication that is similar to semalutide.